SI-BONE Inc 2024年度报告

April 25, 2025 Dear Stockholders:We have made significant and measurable progress since last year’s annual meeting of stockholders, including the following: •Achieved worldwide revenue of $167.2 million for the full year 2024, representing an increase of ~20% over 2023•Over 2,000 physicians performed an iFuse procedure in 2024, an ~25% increase over 2023•Surpassed 115,000 procedures performed by over 4,300 physicians worldwide since inception•Achieved ~29% improvement in Net Loss and ~71% improvement in Adjusted EBITDA year-over-year; deliveredpositive Adjusted EBITDA in the fourth quarter•Exited 2024 with a solid balance sheet with ~$150 million in cash and equivalents•Launched iFuse INTRA, iFuse Bedrock Granite 9.5, and iFuse TORQ TNT in 2024•Granted Transitional Pass-Through payment status effective January 1, 2025 for Granite outpatient procedures•Received third Breakthrough Device Designation for a novel implant system We will hold our Annual Meeting virtually in an effort to make it convenient for our stockholders to attend. During ourAnnual Meeting, we will discuss each item of business described in the Notice of Annual Meeting and Proxy Statementenclosed with this letter, which we encourage you to read carefully. We will also address any questions submitted before orduring the Annual Meeting. Your vote is very important to us, and I urge you to vote your shares as promptly as possible. You may vote by Internet or bytelephone. If you received a paper copy of the proxy card by mail, you may sign, date, and return the proxy card in theenclosed envelope. Finally, I continue to be humbled by the exceptional performance of the entire SI-BONE team, working diligently tointroduce new products and continuing to train and educate physicians to grow our core business. On behalf of the Board,management team and employees, thank you for your continued confidence and support as we advance our mission to helppatients rise up and reach for the stars. We look forward to your participation in this year’s Annual Meeting. Sincerely yours, /s/ Laura FrancisLaura FrancisChief Executive Officer Stock Performance Graph The following graph compares the cumulative total stockholder return data on our common stock with the cumulative returnof three indices: (i) The Nasdaq Stock Market Composite Index, (ii) The Nasdaq Medical Equipment Index, and (iii) TheS&P 500 Healthcare Index over the five-year period ending December 31, 2024. The graph assumes that $100 was investedon December 31, 2019 in our common stock and in each of the comparative indices, and the reinvestment of any dividends.The stock performance on the following graph is not necessarily indicative of future stock price performance. The following graph and related information shall not be deemed "soliciting material" or deemed to be "filed" with the SEC,nor shall such information be incorporated by reference into any future filing, except to the extent that we specificallyincorporate it by reference into such filing. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM10-K (MarkOne) For the fiscalyear ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF1934 FOR THETRANSITION PERIOD FROMTO Commission File Number001-38701 Indicate by check mark if the Registrant is not required to file reports pursuant to Section13 or 15(d)of the Act.Yes☐No Indicate by check mark whether the Registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12months (or forsuch shorter period that the Registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90days.YesNo☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of RegulationS-T (§232.405 of this chapter)during the preceding 12months (or for such shorter period that the Registrant was required to submit such files).YesNo☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See thedefinitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act: If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section7(a)(2)(B) of the Securities Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that